ORIGINAL ARTICLEVEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses
Under a Creative Commons license
open access
Graphical abstract
The expression of VEGF-B was increased and that of IL-22 was decreased in diabetic nephropathy (DN) patients. Anti-VEGFB/IL22 fusion protein combining VEGF-B antibody and IL22 ameliorated DN by alleviating ectopic lipid accumulation, inflammatory responses and insulin resistance.
KEY WORDS
Diabetic nephropathy
Vascular endothelial growth factor B
Interleukin-22
Fusion protein
Abbreviations
ACR
urine albumin-to-creatinine ratio
ADFP
adipocyte differentiation-related protein
AGEs
advanced glycation end products
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BUN
blood urea nitrogen
Ccr
creatinine clearance rate
DN
diabetic nephropathy
ECM
extracellular matrix
eGFR
estimated glomerular filtration rate
ESRD
end-stage renal disease
FA
fatty acid
FATPs
fatty acid transport proteins
GBM
glomerular basement membrane
GSEA
gene set enrichment analysis
H&E
hematoxylin & eosin
HbA1c%
glycosylated hemoglobin
IL-22
interleukin-22
KEGG
Kyoto Encyclopedia of Genes and Genomes
NAC
N-acetyl-l-cysteine
NLRP3
NOD-like receptor family pyrin domain-containing protein 3
NRP-1
neuropilin-1
PAS
periodic acid-Schiff
ROS
reactive oxygen species
SDS-PAGE
SDS-polyacrylamide gel electrophoresis
TEM
transmission electron microscopy
VEGF-B
vascular endothelial growth factor B
VEGFR
vascular endothelial growth factor receptor
β2-MG
β2 microglobulin
Cited by (0)
Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
- †
These authors made equal contributions to this work.
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.